



**HAL**  
open science

# Posturo-locomotor markers of preclinical Parkinson's disease

Leslie M. Decker

► **To cite this version:**

Leslie M. Decker. Posturo-locomotor markers of preclinical Parkinson's disease. *Neurophysiologie Clinique = Clinical Neurophysiology*, 2019, 49 (2), pp.173-180. 10.1016/j.neucli.2019.01.001 . hal-02135252

**HAL Id: hal-02135252**

**<https://hal.science/hal-02135252v1>**

Submitted on 22 Oct 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Posturo-locomotor markers of preclinical Parkinson's disease**

Nathalie Chastan <sup>a, b</sup>, Leslie M. Decker <sup>a</sup>

<sup>a</sup> Normandie Univ, UNICAEN, INSERM, COMETE, Caen, France

<sup>b</sup> Rouen University Hospital, Department of Neurophysiology, Rouen, France

### **Corresponding author:**

Nathalie Chastan, Department of Neurophysiology, Rouen University Hospital–Charles-Nicolle, 1 rue de Germont, 76031 Rouen cedex, France.

Email address: [nathalie.chastan@chu-rouen.fr](mailto:nathalie.chastan@chu-rouen.fr)

Tel.: +33 (0)2 32 88 06 08

## **Abstract**

Parkinson's disease (PD) is known to have a long prodromal stage due to the degeneration of dopaminergic neurons of the substantia nigra pars compacta over the course of many years without clinical manifestations of PD. When the diagnosis is made, the neuropathological process is already well entrenched. Consequently, identifying individuals during this prodromal period could be very helpful for future trials of neuroprotective or disease-modifying therapies, which might slow or prevent the degeneration of dopaminergic neurons. Thus, efforts are needed to determine appropriate early markers of PD. Gait and balance disorders are frequent during the early stages of PD. This systematic review aims to determine if gait and balance disorders occur before the diagnosis of PD and if so, whether they could be used as markers of preclinical PD. Findings reveal that, at the presymptomatic stage of PD, impaired basal ganglia function leads to disorders in gait and balance. Both clinical and instrumental assessments allow early detection of these disorders, particularly when performed under challenging conditions (e.g. dual-task). Among all studied parameters, temporal gait variability and arm kinematics appear to be promising markers of preclinical PD.

**Keyword:** gait and balance disorders, Parkinson's disease, preclinical, prodromal, presymptomatic.

**Running title:** Posturo-locomotor markers of preclinical PD

## **Introduction**

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by classic motor symptoms (i.e., bradykinesia, rigidity, tremor, and postural instability). These motor symptoms are due to loss of dopaminergic nigrostriatal neurons from the substantia nigra pars compacta (SNpc), and only arise after a 70–80% reduction of striatal dopamine, which corresponds to 50% cell death of dopaminergic neurons of the SNpc [34]. There is growing evidence that PD is characterized by a long prodromal period, the neuropathological process beginning about 5 years before the onset of motor symptoms [10]. Identifying individuals during this period could be of great utility for future trials of neuroprotective therapies, which might prevent the degeneration of the dopaminergic neurons [25, 31]. Indeed, when a patient becomes symptomatic, the neuropathological process is already well entrenched. Potential neuroprotective and disease-modifying therapies in the prediagnostic phase may slow or halt irreversible progressive neurodegeneration, and consequently could delay or prevent the clinical symptoms. Hence, efforts are needed to identify robust early markers of preclinical PD. Several studies have focused on detecting PD symptoms in the prodromal phase using a variety of nonmotor biological markers (e.g., olfaction, autonomic dysfunction, sleep disorders, and transcranial sonography of the SNpc). Because PD diagnosis is still largely based on its motor features, it is reasonable to speculate that subtle changes in motor function will be present prior to the appearance of the cardinal motor signs required for diagnosis. The goal of this review is to describe existing posturo-locomotor markers of preclinical PD.

## **Methods**

*Literature search.* The bibliographical search consisted of a literature review through October 2018 using the PubMed database as well as the references cited in the selected articles. Studies were considered eligible if: 1) the data were related to gait and balance disorders, 2) the patients were diagnosed with Parkinson's disease prospectively and/or retrospectively, and 3) the data were collected at a preclinical stage. The search terms included: 1) gait OR locomotion OR walking OR balance OR posture OR postural balance OR postural equilibrium OR accelerometry OR kinematics OR posturography, AND 2) Parkinson's disease OR parkinsonian syndrome OR REM sleep behavior disorder, AND 3) presymptomatic OR asymptomatic OR prodromal OR biomarker OR preclinical OR premanifest. All studies needed to be written in English and to report original data (no review) and human research (no animal research).

*Selection of studies.* After the initial search, all articles were first screened based on their title and abstract. Articles which the two authors (NC and LMD) agreed to be eligible were included. Overall, among the 175 articles initially identified, 140 were excluded based on their title, and 28 were excluded based on their abstract for at least one of the following reasons: 1) no clinical or instrumental assessment of gait and balance, 2) data not collected at the preclinical stage of the disease (e.g., Parkinson's disease de novo). To the remaining seven eligible studies, another four studies were added: three studies extracted from references cited in the seven selected articles and our in press article. Thus, this systematic review included 11 studies (Figure 1).

*Analysis.* For each study, the following data were extracted: population characteristics, description of gait and balance assessments (i.e., types of assessment, tasks and studied parameters), and a summary of findings. No meta-analysis was carried out due to the

limited number of studies available and the diversity of data (e.g., gait and balance parameters, preclinical population etc.).

## **Results**

Eleven articles were selected for this review, including ten cross-sectional studies [6, 7, 9, 18, 21, 22, 24, 26, 27, 36] and one longitudinal study [30]. They are summarized in Table 1. The studied populations were diverse: 1) one study included patients with sporadic idiopathic PD [6], 2) four studies included patients with genetic PD, of which three included LRRK2 gene mutation carriers [22, 24, 36] and one included PINK1 gene mutation carriers [26], and 3) six studies included patients with increased risk of PD, of which five included patients with rapid eye movement (REM) sleep behavior disorder [7, 9, 21, 27, 30] and one included patients with high-risk PD [18]. High-risk PD was defined as the presence of an enlarged area of hyperechogenicity of the substantia nigra and the presence of one of the cardinal symptoms of PD (i.e., bradykinesia or rigidity as assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) - Motor examination). In all studies, patients were compared with age-matched healthy controls. For genetic PD, the control group comprised healthy relatives who were non carriers of the mutation gene in two studies [22, 24] and unrelated controls in two studies [26, 36]. Assessments concerned gait in eight studies [9, 21, 22, 24, 26, 27, 30, 36], balance in two studies [7, 18], and both gait and balance in one study [6]. Clinical assessments of gait and balance were performed in three studies [9, 27, 30], instrumental assessments in seven studies [7, 18, 21, 22, 24, 26, 36], and both clinical and instrumental assessments in one study [6].

## **Discussion**

Impaired basal ganglia function in patients with PD leads to disorders in gait and balance. Changes in gait are obvious in the advanced stage of PD [4, 12], but they are already present in the early stages [2, 11], even before any visible or symptomatic gait disturbances, such as decreased gait speed and increased stride-to-stride variability. Likewise, changes in balance are prominent in the advanced stage of PD, as reflected by the Hoehn & Yahr scale, where postural instability is represented only in the advanced stages 3 to 5 [16]. Nevertheless, postural instability is also present in the early stages before any visible balance disturbances [3, 5, 19]. The result of this review suggests that measures of gait and balance could be used as early markers of preclinical PD.

Both clinical (i.e., Timed Up and Go Test, Stand-Walk-Sit Test, 6-Meter Corridor Walk Test) and instrumental (Vicon®, GAITRite®, 3-axis accelerometer) assessments allow for early detection of gait and balance disorders. Only one study performed concomitant clinical and instrumental gait assessments, with similar results whatever the method used, notably gait slowing [6]. PD affects 1% of people over the age of 65 years and approximately 4% of the population aged over 80 years. In order to detect individuals at risk of developing PD, we need to identify markers which can be used in people aged over 50 years. The method used needs to be easily accessible, simple to use, without specific equipment and with little training, inexpensive and quick. Clinical methods clearly seem to meet all requirements, although further studies are needed to compare the sensitivity and specificity of clinical versus instrumental assessments.

Gait and balance disorders become more apparent under challenging walking (i.e., fast-paced, dual-task) and standing (i.e., vision deprivation, on foam support, in tandem position) conditions, respectively. Challenging the central gait network with demanding tasks is a relevant approach to uncover abnormalities and thus unmask compensatory mechanisms among asymptomatic subjects. Gait variability, as quantified

by the number of step-to-step fluctuations in time (i.e. temporal gait variability) or space (i.e. spatial gait variability), has recently developed into a measure of interest due to its potential utility as a predictive marker of PD and other neurodegenerative conditions [8, 13, 37]. Among the studies reviewed, temporal gait variability was measured in three studies [21, 22, 24] and spatial gait variability in one study [21]. Gait disorders related to preclinical PD manifest through increased temporal gait variability (i.e., stride time variability, double support time variability, and swing time variability). Moreover, impairment in temporal automaticity of gait occurs under challenging conditions (fast pace walking and dual-task walking) without other gait abnormalities, notably preserved gait speed, stride length and stride time [22, 24], suggesting that greater variability in temporal parameters may be particularly sensitive to preclinical PD. Arm kinematics was measured in three studies [24, 26, 36] and seems to provide a sensitive measure of decline in gait function in preclinical PD. Indeed, arm swing variability increases during dual-task walking with no apparent changes in the other studied parameters (i.e., gait speed, stride length and stride time) [24]. Taken together, these findings suggest that temporal gait variability and arm kinematics, particularly under challenging conditions, may represent potential specific markers of preclinical PD.

Preclinical markers are of interest for early identification of people who are likely to develop PD in the future. Nevertheless, whereas idiopathic PD represents 90% of PD, this review underlines the fact that only one study was conducted in individuals who developed idiopathic PD. Other studies concerned individuals with either genetic PD or at higher risk for PD, but preclinical markers derived from these studies cannot necessarily be generalized to the population of patients with idiopathic PD. Genetic PD represents 10% of PD. Many forms of familial PD of Mendelian inheritance have been brought to light, either with recessive inheritance or with dominant inheritance. To date,



two forms of genetic PD have been investigated to identify preclinical markers: LRRK2 gene mutation and PINK1 gene mutation. Mutations in the LRRK2 gene are responsible for 1%-2% of sporadic and 4% of familial PD with autosomal dominant inheritance. Non-manifesting carriers of LRRK2 mutations represent those at higher risk for PD. Hence, the exploration of genetic PD allows evaluation of disease manifestations at the prodromal stage. The phenotype of PD with LRRK2 mutation largely overlaps that of idiopathic PD [20]. Nevertheless, gait disorders in patients with LRRK2 mutation are different to those in patients with idiopathic PD [23, 24], independently of the type of assessment (clinical or instrumental). LRRK2 mutation carriers take longer to perform the Timed Up and Go Test and show more frequent falls and lower gait regularity (i.e., greater stride time variability and arm swing variability). It is possible that the gait network of LRRK2 mutation carriers is simply different, unrelated to the future development of PD (i.e., an endophenotypic marker and not a specific marker of PD) [22]. Moreover, LRRK2 mutations have incomplete and age-dependent penetrance [14]. Incomplete penetrance means that a proportion of the non-manifesting LRRK2 mutation carriers will never develop prodromal symptoms. Age-dependent penetrance means that the risk of PD for a LRRK2 mutation carrier increases with age [14].

Mutations in the PINK1 gene are responsible for familial PD with autosomal recessive inheritance. The phenotype of PD with PINK1 homozygous mutations resembles that of sporadic PD but differs in several aspects. Indeed, PINK1 homozygous mutation carriers show symptoms earlier, slower disease progression, better response to levodopa, but with levodopa-induced dyskinesia in the long term [1]. Therefore, this population provides an opportunity to study the natural course of at least some motor symptoms from the earliest stages of the disease. Individuals with a single heterozygous PINK1 mutation are either clinically asymptomatic or reveal subtle parkinsonian motor

signs, albeit not fulfilling the diagnostic criteria of definite PD [15]. Therefore, it is likely that preclinical markers found in this population cannot necessarily be generalized to a population with sporadic PD.

Patients at high risk of developing PD manifest REM sleep behavior disorder (RBD). RBD is a rare form of REM sleep-related parasomnia with an estimated prevalence rate of 0.5% in the general population [32]. Clinically, polysomnography monitoring is mandatory for accurate diagnosis of RBD, which is characterized by abnormal muscle activity during REM sleep. Abnormalities consist of either sustained muscle activity in REM sleep in chin electromyography (EMG) or as excessive transient muscle activity in REM sleep in chin or limb EMG. RBD patients have excessive motor activity, such as punching, kicking or crying out, in response to dream content during REM sleep, instead of normal muscle atonia. RBD is commonly associated with neurodegenerative disorders characterized by abnormal accumulation of  $\alpha$ -synuclein. Longitudinal studies estimate that over 50% of patients with idiopathic RBD will develop neurodegenerative parkinsonian syndromes, almost exclusively PD, but also multiple system atrophy, progressive supranuclear palsy or dementia with Lewy bodies [17, 29, 33]. As many patients with RBD are at risk of developing PD, it is crucial to identify potential markers of preclinical PD which may be present in patients with RBD. However, patients with RBD and PD have different clinical manifestations (phenotypes) than PD patients without RBD, suggesting that they may present different underlying patterns of neurodegeneration. Specifically, patients with RBD and PD are more prone to falling (38% versus 7%) and less responsive to their medication dose [28]. RBD reflects dysfunction of brainstem regions that regulate both REM sleep and gait control. Thus, these findings should be interpreted cautiously as we cannot exclude the fact that the deficits of idiopathic RBD patients might reflect, at least in part, endophenotypic

markers, and not specific markers of preclinical PD. Moreover, some patients with idiopathic RBD may develop parkinsonian syndrome (and not PD), for whom balance and gait disorders occur earlier, and sometimes represent predominant symptoms, as in progressive supranuclear palsy.

In conclusion, measures of gait and balance could be early markers of preclinical PD. Further studies are needed to identify more specific and more sensitive markers to detect individuals at risk of developing idiopathic PD. To this end, large longitudinal studies should be conducted, in populations experiencing natural aging, in which idiopathic PD cases occur [35], instead of cross-sectional studies among individuals with either genetic PD or at high risk of developing PD. Assessing subtle gait and balance abnormalities may be an inexpensive and efficient method to initially screen for at-risk individuals, that could subsequently be completed by more thorough screening as transcranial sonography of the substantia nigra.

**Acknowledgements:** The authors are grateful to Nikki Sabourin-Gibbs for her help in editing the manuscript.

**Conflicts of interest:** none.

## Reference

- 1 Albanese A, Valente EM, Romito LM, Bellacchio E, Elia AE, Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. *Neurology* 2005;64: 1958-60.
- 2 Baltadjieva R, Giladi N, Gruendlinger L, Peretz C, Hausdorff JM. Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease. *Eur J Neurosci* 2006;24: 1815-20.
- 3 Beuter A, Hernandez R, Rigal R, Modolo J, Blanchet PJ. Postural sway and effect of levodopa in early Parkinson's disease. *Can J Neurol Sci* 2008;35: 65-8.
- 4 Boonstra TA, Van der Kooij H, Munneke M, Bloem BR. Gait disorders and balance disturbances in Parkinson's disease: clinical update and pathophysiology. *Curr Opin Neurol* 2008;21: 461-71.
- 5 Chastan N, Debono B, Maltete D, Weber J. Discordance between measured postural instability and absence of clinical symptoms in Parkinson's disease patients in the early stages of the disease. *Mov Disord* 2008;23: 366-72.
- 6 Chastan N, Bair WN, Resnick SM, Studenski SA, Decker LM. Prediagnostic markers of idiopathic Parkinson's disease: gait, visuospatial ability and executive function. *Gait & Posture* 2018 (in press).
- 7 Chen TZ, Xu GJ, Zhou GA, Wang JR, Chan P, Du YF. Postural sway in idiopathic rapid eye movement sleep behavior disorder: a potential marker of prodromal Parkinson's disease. *Brain Res* 2014;1559: 26-32.
- 8 Collett J, Esser P, Khalil H, Busse M, Quinn L, DeBono K, et al. Insights into gait disorders: walking variability using phase plot analysis, Huntington's disease. *Gait Posture* 2014;40: 694-700.

- 9 Ellmore TM, Hood AJ, Castriotta RJ, Stimming EF, Bick RJ, Schiess MC. Reduced volume of the putamen in REM sleep behavior disorder patients. *Parkinsonism Relat Disord* 2010;16: 645-9.
- 10 Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 1991;114 ( Pt 5): 2283-301.
- 11 Frenkel-Toledo S, Giladi N, Peretz C, Herman T, Gruendlinger L, Hausdorff JM. Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently. *J Neuroeng Rehabil* 2005;2: 23.
- 12 Giladi N. Gait disturbances in advanced stages of Parkinson's disease. *Adv Neurol* 2001;86: 273-8.
- 13 Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. *Mov Disord* 1998;13: 428-37.
- 14 Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 2008;7: 583-90.
- 15 Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. *Arch Neurol* 2006;63: 833-8.
- 16 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17: 427-42.
- 17 Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. *Lancet Neurol* 2006;5: 572-7.

- 18 Maetzler W, Mancini M, Liepelt-Scarfone I, Muller K, Becker C, Van Lummel RC, et al. Impaired trunk stability in individuals at high risk for Parkinson's disease. *PLoS One* 2012;7: e32240.
- 19 Mancini M, Horak FB, Zampieri C, Carlson-Kuhta P, Nutt JG, Chiari L. Trunk accelerometry reveals postural instability in untreated Parkinson's disease. *Parkinsonism Relat Disord* 2011;17: 557-62.
- 20 Marras C, Schule B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. *Neurology* 2011;77: 325-33.
- 21 McDade EM, Boot BP, Christianson TJ, Pankratz VS, Boeve BF, Ferman TJ, et al. Subtle gait changes in patients with REM sleep behavior disorder. *Mov Disord* 2018;28: 1847-53.
- 22 Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. *Ann Neurol* 2011;69: 193-7.
- 23 Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, et al. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation. *Mov Disord* 2013;28: 1683-90.
- 24 Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, et al. Arm swing as a potential new prodromal marker of Parkinson's disease. *Mov Disord* 2016;31: 1527-1534.
- 25 Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann Neurol* 2012;72: 893-901.

- 26 Nurnberger L, Klein C, Baudrexel S, Roggendorf J, Hildner M, Chen S, et al. Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers. *Mov Disord* 2015;30: 386-92.
- 27 Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. *Neurology* 2006;66: 845-51.
- 28 Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. *J Neurol Neurosurg Psychiatry* 2008;79: 1117-21.
- 29 Postuma RB, Montplaisir J. Predicting Parkinson's disease - why, when, and how?. *Parkinsonism Relat Disord* 2009;15 Suppl 3: S105-9.
- 30 Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. *Brain* 2012;135: 1860-70.
- 31 Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. *Neurology* 2015;84: 1104-13.
- 32 Schenck CH, Hurwitz TD, Mahowald MW. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. *J Sleep Res* 1993;2: 224-231.
- 33 Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. *Neurology* 1996;46: 388-93.

- 34 Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. *Ann Neurol* 1989;26: 551-7.
- 35 Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm (Vienna)* 2017;124: 901-905.
- 36 Van den Heuvel L, Lim AS, Visanji NP, Huang J, Ghate T, Mestre TA, et al. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. *J Parkinsons Dis* 2018;8: 131-139.
- 37 Webster KE, Merory JR, Wittwer JE. Gait variability in community dwelling adults with Alzheimer disease. *Alzheimer Dis Assoc Disord* 2006;20: 37-40.



**Table 1.** Summary of the articles selected for the review.

## **Figure legends**

**Figure 1.** Flow-chart.

175 studies initially identified from PubMed database

Studies excluded based on the title (n = 140)

35 eligible studies

Studies excluded based on the abstract (n = 28)

7 selected studies

Inclusion of:  
- articles from references cited in selected manuscripts (n = 3)  
- one article in press (n = 1)

**11 selected studies**